| 000 | 01068 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250514192947.0 | ||
| 264 | 0 | _c20040716 | |
| 008 | 200407s 0 0 eng d | ||
| 022 | _a1476-4687 | ||
| 024 | 7 |
_a10.1038/430030a _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStratton, Michael R | |
| 245 | 0 | 0 |
_aCancer: understanding the target. _h[electronic resource] |
| 260 |
_bNature _cJul 2004 |
||
| 300 |
_a30 p. _bdigital |
||
| 500 | _aPublication Type: News | ||
| 650 | 0 | 4 | _aEnzyme Activation |
| 650 | 0 | 4 |
_aEpidermal Growth Factor _xpharmacology |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aMutation _xgenetics |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 |
_aQuinazolines _xpharmacology |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 700 | 1 | _aFutreal, P Andrew | |
| 773 | 0 |
_tNature _gvol. 430 _gno. 6995 _gp. 30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/430030a _zAvailable from publisher's website |
| 999 |
_c14933999 _d14933999 |
||